마취용 CO2 흡수제 시장 보고서 : 제품별, 유형별, 최종사용자별, 지역별(2026-2034년)

The global anesthesia CO2 absorbent market size reached USD 87.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 136.8 Million by 2034, exhibiting a growth rate (CAGR) of 4.96% during 2026-2034. The increasing number of surgeries across hospitals and clinics is raising the demand for reliable absorbents, which is stimulating the market.

ANESTHESIA CO2 ABSORBENT MARKET ANALYSIS:

• Major Market Drivers: The growing focus on improving patient safety during anesthesia procedures is promoting the use of high-quality CO2 absorbents, thereby propelling the market.
• Key Market Trends: The development of new absorbent technologies that minimize waste and increase efficiency is acting as a significant growth-inducing factor.
• Competitive Landscape: Some of the major market companies include Armstrong Medical Ltd. (Eakin Healthcare Group Ltd), Atrasorb, Dragerwerk AG & Co. KGaA, General Electric Company, Intersurgical Ltd., Lowenstein Medical SE & Co. KG, Micropore Inc., Molecular Products Group plc (Filtration Group Corporation), and Smiths Medical Inc. (ICU Medical Inc.), among many others.
• Geographical Trends: North America exhibits a clear dominance in the market due to advanced healthcare systems, high surgical volumes, and a strong focus on patient safety, further contributing to market growth.
• Challenges and Opportunities: The potential for compound formation during use is hindering the market. However, developing advanced absorbents that minimize harmful byproducts and enhance patient safety will continue to strengthen the market over the forecast period.

ANESTHESIA CO2 ABSORBENT MARKET TRENDS:

Growing Demand for Eco-Friendly Solutions

Healthcare providers are increasingly seeking CO2 absorbents that minimize harmful side effects, as environmental concerns are growing. In addition, eco-friendly absorbents reduce the ecological footprint of anesthesia practices and align with sustainability initiatives within hospitals, thereby promoting safer alternatives that contribute to a healthier environment while maintaining effective patient care. For instance, in May 2024, according to an article published by Bell Medical Inc., the sodium hydroxide-free amsorb plus CO2 absorbent is promoting eco-friendly anesthesia by preventing harmful byproducts, and enabling low fresh gas flow techniques, thereby reducing anesthetic agent pollution, improving sustainability, and elevating anesthesia CO2 absorbent market scope.

Advancements in Low-Flow Anesthesia Technologies

The rising shift towards low-flow anesthesia techniques enhances patient outcomes and reduces wasteful gas usage. Moreover, innovations in CO2 absorbents that support these technologies facilitate doctors to maintain effective ventilation with lower fresh gas flows, thereby optimizing resource utilization and ensuring efficient gas management in surgical environments. For instance, in August 2024, Penlon launched the E-Flo 6C anesthesia machine, featuring absorber and CO2 monitoring, thereby enhancing safety and precision in low-flow anesthesia through advanced ventilation control and comprehensive gas monitoring systems. As per the anesthesia CO2 absorbent market segmentation, this is acting as a significant growth-inducing factor.

Improved Integration of CO2 Absorption Systems

Enhanced integration of CO2 absorption within anesthesia machines simplifies the operational setup, reducing the need for multiple connections between components. In contrast, this leads to faster assembly and improved usability, making it simpler to manage anesthesia procedures efficiently while ensuring optimal CO2 absorption performance, particularly in critical anesthesia environments. For instance, in October 2024, Philips introduced the Siesta i Whispa anesthesia machine, an integrated breathing system (IBS) with an ascending bag-in-bottle and CO2 absorber. This innovation streamlines connections between the machine and patient, reducing setup time and improving cleaning efficiency.

GLOBAL ANESTHESIA CO2 ABSORBENT INDUSTRY SEGMENTATION:

Breakup by Product:

• Soda Lime
• Medisorb
• Dragersorb
• Amsorb
• Litholyme
• Others

Medisorb currently hold the largest anesthesia CO2 absorbent market share

Medisorb exhibits a clear dominance in the market due to its efficient CO2 absorption capabilities, which enhance patient safety during procedures. For example, Medisorb EF was launched to minimize compound formation, thereby ensuring better anesthesia care while reducing environmental impact in medical settings.

Breakup by Type:

• Premium
• Traditional

Premium currently holds the largest anesthesia CO2 absorbent market demand

The premium segment dominates the market due to its high efficiency, longer-lasting performance, and superior safety features. For example, Drager launched its premium product 'Dragersorb' with enhanced CO2 absorption capabilities, which reduces the risk of compound A formation, ensuring patient safety during anesthesia procedures.

Breakup by End User:

• Hospitals
• Clinics
• Others

Hospital exhibits the largest anesthesia CO2 absorbent market outlook

Hospitals lead the market as the primary end users, driven by the need for efficient patient care during surgeries. For example, GE Healthcare launched Aisys CS2, an advanced anesthesia machine incorporating CO2 absorbents to enhance safety and reduce environmental impact.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the market

The anesthesia CO2 absorbent market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the anesthesia CO2 absorbent market overview, North America dominates the market, which is driven by well-established healthcare systems, high surgical volumes, and innovative advancements. In addition, the region's dominance is also supported by growing awareness of patient safety and effective waste gas management during surgeries. For example, Drager launched its 'Dragersorb Free' absorbent, a CO2 absorbent designed to prevent the formation of toxic compounds during anesthesia. Furthermore, such innovations highlight North America's role in advancing safe and efficient anesthesia practices.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all market companies have also been provided. Some of the key players in the market include:

• Armstrong Medical Ltd. (Eakin Healthcare Group Ltd)
• Atrasorb
• Dragerwerk AG & Co. KGaA
• General Electric Company
• Intersurgical Ltd.
• Lowenstein Medical SE & Co. KG
• Micropore Inc.
• Molecular Products Group plc (Filtration Group Corporation)
• Smiths Medical Inc. (ICU Medical Inc.)

()

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the global anesthesia CO2 absorbent market?

2. What is the expected growth rate of the global anesthesia CO2 absorbent market during 2026-2034?

3. What are the key factors driving the global anesthesia CO2 absorbent market?

4. What has been the impact of COVID-19 on the global anesthesia CO2 absorbent market growth?

5. What is the breakup of the global anesthesia CO2 absorbent market based on the product?

6. What is the breakup of the global anesthesia CO2 absorbent market based on the type?

7. What is the breakup of the global anesthesia CO2 absorbent market based on the end user?

8. What are the key regions in the global anesthesia CO2 absorbent market?

9. Who are the key players/companies in the global anesthesia CO2 absorbent market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Anesthesia CO2 Absorbent Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Soda Lime
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Medisorb
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Dragersorb
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Amsorb
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Litholyme
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Type

• 7.1 Premium
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Traditional
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Armstrong Medical Ltd. (Eakin Healthcare Group Ltd)
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Atrasorb
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Dragerwerk AG & Co. KGaA
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 General Electric Company
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Intersurgical Ltd.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 SWOT Analysis
  • 14.3.6 Lowenstein Medical SE & Co. KG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Micropore Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Molecular Products Group plc (Filtration Group Corporation)
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Smiths Medical Inc. (ICU Medical Inc.)
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 SWOT Analysis